CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to develop small molecules that can activate cell death pathways in cancer cells without harming healthy cells. It focuses on creating novel compounds that mimic the action of existing cancer treatments.
Death Receptors (DR), members of the tumour necrosis factor (TNF) receptor family, have come into focus as suitable targets for the selective activation of the cell death (apoptosis) pathway in tumours in vivo without causing toxicity to healthy cells.
Current approaches in clinical development for replicating the function of the TNF-related apoptosis inducing ligand (TRAIL) are restricted to recombinant proteins which have poor pharmacokinetic properties due to their susceptibility to proteolyt…
UNIVERSITE BORDEAUX I
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
